Matinas BioPharma successfully completes warrant tender offer – raises $13.5 million
Matinas BioPharma announced the successful completion of its tender offer to amend and exercise certain categories of existing warrants, which expired at Jan. 13, 2017. Net cash proceeds, after deducting warrant solicitation agent fees and other estimated offering expenses, totaled $12.7 million. January 19, 2017